• 1. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

• 2. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

• 3. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

• 4. Prognostic factors for survival in adult patients with cerebral low-grade glioma.

• 5. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

• 6. SMART syndrome: a late reversible complication after radiation therapy for brain tumours.
• rare syndrome